Find the latest news from NanoValent and its global strategic partners
2025
April 21, 2025
NanoValent presents new data at AACR (Chicago) on enhancing GBM therapy with tumor-targeted nanoparticles
2024
April 3, 2024
NanoValent presents new data at AACR (San Diego) on tumor-targeted nanoparticles for cancer therapy
2023
August 8, 2023
NanoValent confirms receipt of STTR funding award in GBM
April 17, 2023
NanoValent presents extensive new data with NV103 in CD99-expressing tumor models at AACR (Orlando)
2021
April 18, 2021
A more Targeted Approach in Pediatric Cancer Therapy? (Onco’Zine)
January 11, 2021
Nanovalent Presents New Data at Biotech Showcase 2021 Including Significant GBM Data.
2020
January 8, 2020
NanoValent Pharmaceuticals Announces the Publication of US Patent Targeted Polymerized Nanoparticles for Cancer Treatment
2019
August 20, 2019
NanoValent Pharmaceuticals Announces Issuance of United States
Patent for Application of Targeted Polymerized Nanoparticles in
Cancer Treatment
April 3, 2019
Anti-CD99 Targeted Nanosphere Shows Potential in Ewings Sarcoma
2018
October 1, 2018
NanoValent Receives NIH SBIR Funding for Antibody-conjugated Nanoparticle Technology
2017
October 10, 2017
NanoValent Pharmaceuticals Announces Exclusive Global Licensing Agreement with Children’s Hospital Los Angeles and Completion of First Wave of Financing
January 10, 2017
NanoValent Appoints Timothy Enns as Chief Executive Officer
2014
April 17, 2014
NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals
2008
January 10, 2008
NanoValent Pharmaceuticals Acquires Targesome, Inc. Intellectual Property
Disclaimer: The information contained in each news/press release posted on this page was factually accurate on the date it was issued. Nanovalent Pharmaceuticals assumes no duty to update the information to reflect subsequent developments. Readers of the news releases should not rely upon the information as current or accurate after their issuance dates. Information about investigational pharmaceutical products currently in development included in the press releases is not intended to constitute an advertisement or medical advice. Furthermore, the safety and efficacy of any investigational pharmaceutical products in these press releases has not been established for the use(s) being considered. Finally, there is no guarantee that the investigational pharmaceutical products in these press releases will receive regulatory approval and become commercially available for the use(s) being investigated.